Portal de Periódicos da CAPES

Gamma glutamyl transferases in association with cardiovascular risk scores in non-diabetic hypertensive Cameroonians: preliminary data from HYRICCA study

2022; BioMed Central; Volume: 15; Issue: 1 Linguagem: Inglês

10.1186/s13104-022-06190-1

1756-0500

Jan René Nkeck, Chemgne Marie Ida, Valerie Ndobo Koe, Antonin Wilson Ndjitoyap Ndam, Yondo Ndedi Claudine Jessica, Eko Ondoa Manuella, Boukeu Yonta Charelle, Zouague Zalbi Corine, Ntyam Abena Andrée, Falmata Amazia, Jériel Pascal Nkeck, Esther Astrid Mbono Samba, Vicky Jocélyne Ama Moor,

Folate and B Vitamins Research

The usefulness of gamma glutamyl transferase (GGT) as biomarker of cardiovascular risk (CVR) remains unexplored in sub-Saharan Africans. To evaluate their relevance on CVR assessment in non-diabetic hypertensive Cameroonians. This was a prospective cross-sectional study on non-diabetic hypertensive adults aged 57.7 ± 10 years (62% female), without evidence of acute or chronic liver disease, in which we assessed GGT levels and correlates it with validated CVR biomarkers, CVR scores (WHO risk score, Framingham 2008, ASCVD 2013, EuroSCORE 2003, and Reynolds score), and plasma atherogenic index (PAI).We found a positive but weak association between GGT and PAI on linear regression [0.004 (0.001; 0.007); p = 0.021], which was dependent of triglycerides levels (r = 0.17; p = 0.03). We did not find a significant association between GGT levels and the results of the CVR scores studied; Although being related to atherogenic risk, as reported in literature in non-sub-Saharan Africans, GGTs would be of little value for CVR assessment in our population.